Abiopharma

Community Health Systems, Inc. Announces Early Tender Results for Its 5.625% Senior Secured Notes Due 2027

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

A New Press Release from Theriva Biologics, Inc.

New Form 8-K/A - Esperion Therapeutics, Inc. Filed: 2025-08-11 AccNo: 0001628280-25-039392 Size: 270 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Inspire Medical Systems, Inc. - Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program

New Form S-8 - Karyopharm Therapeutics Inc. Filed: 2025-08-11 AccNo: 0001193125-25-177472 Size: 177 KB

IO Biotech, Inc. - IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial ofCylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

New Form 8-K - IO Biotech, Inc. Filed: 2025-08-11 AccNo: 0001193125-25-177471 Size: 3 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 3 - Tenon Medical, Inc. Filed: 2025-08-11 AccNo: 0001213900-25-073935 Size: 4 KB

180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes

New Form 8-K - ArriVent BioPharma, Inc. Filed: 2025-08-11 AccNo: 0001558370-25-010974 Size: 367 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025

ArriVent BioPharma Reports Second Quarter 2025 Financial Results